Liver steatosis and in-out of phase MR imaging: Theory and clinical applications at 3T;Stéatose hépatique et séquence phase-opposition de phase: Aspects théoriques et applications pratiques à 3T

Journal de Radiologie

Volumn 88, Issue 12, 2007, Pages 1845-1853

  Guiu, B ^a   Loffroy, R ^a   Ben Salem, D ^a   Masson, D ^b   Herve G ^a   Petit, J M ^a   Krause D ^a   Cercueil, J P ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Institut Médical de Génétique et d Immunologie   (France)

Author keywords

Liver; Liver steatosis; MRI

Indexed keywords

CLINICAL FEATURE; CLINICAL PRACTICE; ERROR; HEPATOGRAPHY; HISTOLOGY; HUMAN; LIVER BLOOD VESSEL; LIVER TRANSPLANTATION; MICROVASCULATURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW;

EID: 38149027086     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(07)78362-2     Document Type: Article

References (34)

1. Charatcharoenwitthaya P, Lindor KD. Role of Radiologic Modalities in the Management of Non-alcoholic Steatohepatitis. Clin Liver Dis 2007;11:37-54.
2. Chevallier P. [What can we expect from non invasive imaging methods to detect and grade liver fatty infiltration?]. Gastroenterol Clin Biol 2005;29:1133-5.
3. Hussain HK, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, et al. Hepatic fat fraction: MR imaging for quantitative measurement and display - early experience. Radiology 2005;237:1048-55.
4. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
5. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-7.
6. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26(Suppl. 1):13-22.
7. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26(Suppl. 2):43-53.
8. Lahmek P, Nahon S. Stéatopathies hépatiques non alcooliques. Encyclopédie Médico-Chirurgicale. 2005; Traité d'Hépato-Gastroentérologie:269-89.
9. Murray R, Granner D, Mayes P, Rodwell V. Biochimie de Harper. Paris: De Boeck Université 2003.
10. Grimaldi A. Diabète de type 2. Paris: Elsevier; 2004.
11. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
12. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35:531-7.
13. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664-71.
14. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
15. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105-13.
16. Perez-Daga JA, Santoyo J, Suarez MA, Fernandez-Aguilar JA, Ramirez C, Rodriguez-Canete A, et al. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. Transplant Proc 2006;38:2468-70.
17. Ben Mosbah I, Casillas-Ramirez A, Xaus C, Serafin A, Rosello-Catafau J, Peralta C. Trimetazidine: is it a promising drug for use in steatotic grafts? World J Gastroenterol 2006;12:908-14.
18. Fernandez L, Carrasco-Chaumel E, Serafin A, Xaus C, Grande L, Rimola A, et al. Is ischemic preconditioning a useful strategy in steatotic liver transplantation? Am J Transplant 2004;4:888-99.
19. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004;40:933-41.
20. Alwayn IP, Porte RJ. How to make steatotic livers suitable for transplantation. Liver Transpl 2007;13:480-2.
21. Lautamaki R, Borra R, Iozzo P, Komu M, Lehtimaki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006;291:E282-90.
22. Gruttadauria S, Vasta F, Minervini MI, Piazza T, Arcadipane A, Marcos A, et al. Significance of the effective remnant liver volume in major hepatectomies. Am Surg 2005;71:235-40.
23. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6:1-28.
24. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
25. Merkle EM, Nelson RC. Dual gradient-echo in-phase and opposed-phase hepatic MR imaging: a useful tool for evaluating more than fatty infiltration or fatty sparing. Radiographics 2006;26:1409-18.
26. Chave G, Milot L, Pilleul F. Imagerie par résonance magnétique en opposition de phase et ses applications hépatiques. J Radiol 2005;86:993-7.
27. Yu JS, Park JG, Jeong EK, Park MS, Kim KW. Hepatic MRI using the double-echo chemical shift phase-selective gradient-echo technique. AJR Am J Roentgenol 2007;188:W49-56.
28. Savci G, Yazici Z, Sahin N, Akgoz S, Tuncel E. Value of chemical shift subtraction MRI in characterization of adrenal masses. AJR Am J Roentgenol 2006;186:130-5.
29. Mitchell DG, Stolpen AH, Siegelman ES, Bolinger L, Outwater EK. Fatty tissue on opposed-phase MR images: paradoxical suppression of signal intensity by paramagnetic contrast agents. Radiology 1996;198:351-7.
30. Prasad SR, Wang H, Rosas H, Menias CO, Narra VR, Middleton WD, et al. Fat-containing lesions of the liver: radiologicpathologic correlation. Radiographics 2005;25:321-31.
31. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007;46:521-7.
32. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-24.
33. Kim SH, Lee JM, Han JK, Lee JY, Lee KH, Han CJ, et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging - correlation with histopathologic findings. Radiology 2006;240:116-29.
34. De Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004;230:652-9.